AIs	aromatase inhibitors
ASCO	American Society of Clinical Oncology
BCa	Breast cancer
BM	bone metastases
BMFS	bone metastases-free survival
BPs	bisphosphonates
BTA	bone-targeted agent
CRPC	castration-resistant prostate cancer
CTCs	circulating cancer cells
DC	dendritic cells
EBCTCG	Early Breast Cancer Trialists’ Collaborative Group
EMT	epithelial-to-mesenchymal transition
ER	estrogen receptor
ESMO	European Society for Medical Oncology
ET	endocrine therapy
HR	hormone receptor
ICI	immune checkpoint inhibitor
IGFs	insulin-like growth factors
IHC	immunohistochemistry
MM	multiple myeloma
MPA	medroxy-progesterone acetate
NSCLC	non-small cell lung cancer
OPG	osteoprotegerin
ORR	objective response rate
OS	overall survival
PCa	prostate cancer
PFS	progression-free survival
PR	progesterone receptor
RANKL	receptor activator of nuclear factor-κB ligand
RCC	renal cell carcinoma
RCTs	randomized clinical trials
SREs	skeletal-related events
TAMs	tumor-associated macrophages
TILs	tumor infiltrating lymphocytes
TKIs	tyrosine kinase inhibitors
TNBCa	triple-negative breast cancer
ZA	zoledronate